Abstract
Adeno-associated virus (AAV) vectors are extensively used for gene therapy clinical trials. Accurate and standardized titration methods are essential for characterizing and dosing AAV-based drugs and thus to assess their safety and efficacy. To this end, the Reference Standard Materials (RSM) working group generated standards for AAV serotype 2 and serotype 8. The AAV8RSM (ATCC® VR-1816™) was deposited to the American Type Culture Collection in 2014 and is available to the scientific community. Here, three independent laboratories of the RSM working group provide stability data of the AAV8RSM 2 years after the initial characterization and after container relabeling performed at the ATCC. The AAV8RSM showed constant titers across experimental conditions: 1.48 ± 0.62 × 1012 vector genome (vg)/ml, 9.38 ± 11.4 × 108 infectious units (IU)/ml and 5.76 ± 2.39 × 1011 total particles (p)/ml as determined by qPCR, TCID50 and ELISA, respectively. Additionally, the AAV8RSM capsid protein integrity assessed by SDS-PAGE was equivalent to the original analyses. In conclusion, the AAV8RSM titers remained stable for two years under appropriate storage conditions ( <−70° C). The use of RSM is strongly recommended and endorsed by regulatory agencies to normalize laboratory internal controls and to provide accurate titration of AAV vectors lots.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Aucoin MG, Perrier M, Kamen AA. Critical assessment of current adeno-associated viral vector production and quantification methods. Biotechnol Adv. 2008;26:73–88.
Clement N, Grieger JC. Manufacturing of recombinant adeno-associated viral vectors for clinical trials. Mol Ther Methods & Clin Dev. 2016;3:16002.
Schnodt M, Buning H. Improving the quality of adeno-associated viral vector preparations: the challenge of product-related impurities. Human gene Ther Methods. 2017;28:101–8.
Wilson JM. A call to arms for improved vector analytics! Human gene Ther Methods. 2015;26:1–2.
Lock M, McGorray S, Auricchio A, Ayuso E, Beecham EJ, Blouin-Tavel V, et al. Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material. Hum Gene Ther. 2010;21:1273–85.
Ayuso E, Blouin V, Lock M, McGorray S, Leon X, Alvira MR, et al. Manufacturing and characterization of a recombinant adeno-associated virus type 8 reference standard material. Hum Gene Ther. 2014;25:977–87.
Moullier P, Snyder RO. Recombinant adeno-associated viral vector reference standards. Methods Enzymol. 2012;507:297–311.
Moullier P, Snyder RO. International efforts for recombinant adeno-associated viral vector reference standards. Mol Ther. 2008;16:1185–8.
Gavin DK. FDA statement regarding the use of adeno-associated virus reference standard materials. Human gene Ther Methods. 2015;26:3.
Lock M, Alvira MR, Chen SJ, Wilson JM. Absolute determination of single-stranded and self-complementary adeno-associated viral vector genome titers by droplet digital PCR. Human gene Ther Methods. 2014;25:115–25.
D’Costa S, Blouin V, Broucque F, Penaud-Budloo M, Francois A, Perez IC, et al. Practical utilization of recombinant AAV vector reference standards: focus on vector genomes titration by free ITR qPCR. Mol Ther Methods Clin Dev. 2016;5:16019.
Allay JA, Sleep S, Long S, Tillman DM, Clark R, Carney G, et al. Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. Hum Gene Ther. 2011;22:595–604.
Acknowledgements
We thank ATCC for their contribution labeling the vials and sending materials to the testing laboratories involved in this study. We thank Sven Kuhlendahl and Progen team for providing data, helpful discussions and the ELISA kits used in this study along with Diego Matayoshi, Kristy Guo, Jessica Stone and Kathy Lastra at Brammer Bio. Financial support to E.A.’s laboratory was provided by INSERM, University of Nantes, CHU of Nantes, Fondation d’Entreprises pour la Thérapie Génique en Pays de la Loire, and Région Pays de la Loire and Pre-industrial gene therapy consortium (Agence Nationale de la Recherche - Investissements d’Avenir, grant number 10-DPBS-0001).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
ROS is an inventor on patents related to recombinant AAV technology. ROS owns equity in a gene therapy company that is commercializing AAV for gene therapy applications. To the extent that the work in this manuscript increases the value of these commercial holdings, ROS has a conflict of interest. ML is an inventor on patents related to recombinant AAV technology. The other authors declare that they have no conflict of interest.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Penaud-Budloo, M., Broucque, F., Harrouet, K. et al. Stability of the adeno-associated virus 8 reference standard material. Gene Ther 26, 211–215 (2019). https://doi.org/10.1038/s41434-019-0072-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41434-019-0072-9
This article is cited by
-
Analysis of the impact of pluronic acid on the thermal stability and infectivity of AAV6.2FF
BMC Biotechnology (2024)